Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CaspoNEB: Caspofungin Aerosols for Pneumocystis Pneumonia
NCT06892951Phase 2Recruiting
- Sponsor
- University Hospital Tours
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of caspofungin in pneumocystis pneumonia (PCP) (3 arms), sponsored by University Hospital Tours. Primary endpoints: Safety of inhaled caspofungin at 7 days and Proportion of patients alive and with a favorable clinical course at 7 days. Started Dec 2025; status: recruiting.
02
Drugs
caspofungin
03
Conditions
pneumocystis pneumonia (PCP)
Beyond the preview
Go deeper on NCT06892951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06892951.